Bovilis Ibr Marker Live, Lyophilisate And Solvent For Suspension For Cattle
Revised: December 2014
SUMMARY OF PRODUCT CHARACTERISTICS
NAME OF THE VETERINARY MEDICINAL PRODUCT
Bovilis IBR Marker Live, Lyophilisate and Solvent for Suspension for Cattle
QUALITATIVE AND QUANTITATIVE COMPOSITION
Per dose of 2 ml reconstituted vaccine:
BHV-1, strain GK/D (gE¯ ): 105.7 - 107.3 TCID50.
TCID50: tissue culture infective doses 50%
For the full list of excipients, see section 6.1.
Lyophilisate and solvent for suspension.
Lyophilisate: off-white to light pink-coloured pellet.
Solvent: colourless solution
Indications for use, specifying the target species
Active immunisation of cattle to reduce the intensity and duration of the clinical respiratory signs induced by an infection with BHV-1 and to reduce nasal excretion of field virus.
Onset of immunity:
An increase in immunity was demonstrated 4 days after intranasal vaccination and 14 days after intramuscular vaccination of 3 month old seronegative animals.
Duration of immunity:
After intranasal administration to 2 week old calves without maternal antibodies, immunity lasts at least until the age of 3-4 months, when the animals should be revaccinated. In the presence of maternally derived antibodies, the protection of the vaccine may not be complete until this revaccination.
Revaccination at 3-4 months of age results in protective immunity that lasts for at least 6 months.
Single intranasal or intramuscular vaccination of 3 month old animals provides protective immunity (reduction of clinical signs and reduction of viral excretion), which was demonstrated via challenge 3 weeks after vaccination. Reduction of viral excretion is maintained for at least 6 months after single vaccination.
No information is available on the efficacy of the vaccine to prevent a latent wild virus infection or to prevent wild virus re-excretion in the latent carrier.
The presence of maternal antibodies can influence the efficacy of the vaccination. Therefore it is recommended to ascertain the immune status of calves before vaccination is started.
Animals between the age of 2 weeks and 3 months should be vaccinated via the intranasal route only and the animals should be revaccinated via the intranasal or intramuscular route when the animals are 3-4 months old.
Special precautions for use
Special precautions for use in animals
Vaccinate only healthy animals.
After intranasal administration, the vaccine virus may spread to in-contact cattle. Cattle which need to remain totally free from BHV 1 antibodies should be separated from intranasally vaccinated animals.
Special precautions to be taken by the person administering the veterinary medicinal product to animals
In case of accidental self injection, seek medical advice immediately and show the package leaflet or the label to the physician.
Adverse reactions (frequency and seriousness)
A slight transient rise in temperature (1C) can occur up to 5 days post vaccination.
An increase of nasal discharge can be observed after intranasal vaccination.
Use during pregnancy, lactation or lay
Can be used during pregnancy and lactation.
No information is available on the use of this vaccine in breeding bulls.
Interaction with other medicinal products and other forms of interaction
Safety and efficacy data -in cattle from 3 weeks of age onwards- are available which demonstrate that this vaccine can be administered on the same day but not mixed with Bovilis Bovipast RSP.
Safety and efficacy data are available which demonstrate that for the 6-monthly intramuscular re-vaccination -in cattle from 15 months of age onwards (i.e. those that have previously been vaccinated separately with Bovilis IBR marker live and Bovilis BVD)- this vaccine can be mixed and administered with Bovilis BVD. The product literature of Bovilis BVD should be consulted before administration of the mixed products. The adverse effects observed after administration of one dose or an overdose of the mixed vaccines are not different from those described for the vaccines administered separately.
When mixed with Bovilis BVD at re-vaccination, the demonstrated efficacy claims for Bovilis IBR marker live are as follows:
Active immunisation of cattle to reduce the fever induced by an infection with BHV-1 and to reduce nasal excretion of field virus.
Duration of immunity: 6 months demonstrated by serological data.
No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product except the products mentioned above. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.
Do not use together with immunosuppressive agents
Amounts to be administered and administration route
Reconstitute the vaccine with the solvent Unisolve
Number of doses per vial
Volume (ml) of solvent needed
Number of doses per vial Volume (ml) of solvent needed
Dosage: a single dose of 2 ml reconstituted vaccine per animal
Method of administration:
- from the age of 3 months onwards: intranasal or intramuscular.
- at an age between 2 weeks and 3 months: intranasal
For intranasal administration (1 ml in each nostril), the use of a nozzle is recommended.
- Basic vaccination:
Vaccinate each animal with one single dose.
When the first vaccination is given between the age of 2 weeks and 3 months, the animals should be revaccinated with a single dose at the age of 3-4 months. Afterwards, revaccinate every 6 months.
When vaccination is started after the animals are 3 months old, the animals should be revaccinated with a single dose every 6 months.
For the 6-monthly revaccination, the vaccine may be reconstituted shortly before use with Bovilis BVD for use in cattle from 15 months of age (i.e. those that have previously been vaccinated separately with Bovilis IBR marker live and Bovilis BVD) and the following instructions should be used:
Bovilis IBR marker live Bovilis BVD
5 doses + 10 ml
10 doses + 20 ml
25 doses + 50 ml
50 doses + 100 ml
A single dose (2 ml) of Bovilis IBR marker live mixed with Bovilis BVD is given intramuscularly.
Use sterile vaccination equipment free from disinfectants. To prevent the spread of any infective agents the intranasal equipment should be changed at each animal.
Visual appearance after reconstitution
In Unisolve: colourless to slightly opaque solution
In Bovilis BVD: as specified in the product information for Bovilis BVD alone.
Overdose (symptoms, emergency procedures, antidotes)
At 10-fold overdose, no other effects than described under section 4.6 have been observed
Pharmacotherapeutic group: live herpes virus vaccine
ATC-vet code: QI02AD01
To stimulate active immunity against bovine herpesvirus type 1 (BHV-1). The vaccine does not elicit antibodies to glycoprotein E of BHV-1 (marker vaccine). This enables discrimination between cattle vaccinated with this product and cattle infected with BHV-1 field virus or vaccinated with conventional non-marker BHV-1 vaccines.
List of excipients
Veggie medium, chemically defined stabiliser CD#156 (patented)
Sucrose, potassium and sodium phosphate buffers, sodium chloride, water for injections.
Do not mix with any other veterinary medicinal product, except the diluent supplied for use with the veterinary medicinal product or with Bovilis BVD (for 6-monthly revaccination only).
Shelf life of the veterinary medicinal product as packaged for sale:
Lyophilisate: 36 months
Solvent: in glass vials: 60 months; in PET vials: 18 months
Shelf life after reconstitution according to directions: 3 hours.
Shelf life after mixing with Bovilis BVD: 3 hours
Special precautions for storage
Store in a refrigerator (2°C - 8°C).
Do not freeze
Protect from light
Store below 25°C.
Do not freeze
Vaccine after reconstitution: below 25°C
After mixing with Bovilis BVD: below 25°C
Nature and composition of immediate packaging
Cardboard box with 1 or 10 vials of glass (hydrolytic type I) with rubber stopper and metal cap.
Contents per vial: 5, 10, 25, 50 or 100 doses
Cardboard box with 1 or 10 vials of glass (hydrolytic type II) or plastic (polyethylene terephthalate) with rubber stopper and metal cap.
Contents per vial:
Glass: 10, 20, 50, 100 or 200 ml
PET: 100 ml
Not all pack sizes may be marketed
Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products
Dispose of waste material by boiling, incineration, or immersion in an appropriate disinfectant in accordance with national requirements.
MARKETING AUTHORISATION HOLDER
Intervet International BV
Intervet UK Ltd
MARKETING AUTHORISATION NUMBER
DATE OF FIRST AUTHORISATION
Date: 13 February 2002
DATE OF REVISION OF THE TEXT
Date: December 2014
PROHIBITION OF SALE, SUPPLY AND/OR USE
Subject to medical prescription (NL: UDD)
According to article 71 of Council Directive 2001/82/EC, Member States may prohibit the import, sale, supply and/or use of Bovilis IBR marker on the whole or part of their territory pursuant to national animal health policy.
Revised (typographical error 4.8):
01 December 2014
Page 6 of 6